All In Biotech

Drug Trial Radar · NCT04791345

Study of the Excretion of Orally Administered Corticosteroids for the Improval of the Detection of Said Substances in Anti-doping Controls

Last checked: Nov 19, 2026Latest source record: Apr 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

Feb 26, 2021

Primary completion

Feb 26, 2022

Study completion Feb 26, 2022

Sponsor

Lead sponsor
Parc de Salut MarAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Background: Glucocorticoids (GC) were included in the list of banned substances in sports in 1986, because of evidences of positive effects on physical performance and the important health risks associated with its consumption. Due to the fact that GC are commercialized in a variety of pharmaceutical forms and are administered in different ways, it is necessary to establish discrimination criteria to guarantee the therapeutic use of these drugs and to prevent doping. Hypothesis: Discrimination criteria between allowed and prohibited administrations of GC must be specific for each of the compounds. Further studies are needed to provide discrimination criteria related to oral administration of GC. Objectives: To conduct excretion studies with dexamethasone, methylprednisolone and deflazacort in order to define notification levels and wash-out periods after the administration of a single dose (DEX, MP and DEF) or repeated doses (DEX and MP) of these drugs. Methods: Non-randomized, open-label, pharmacokinetics clinical trial where a single dose of DEF, MP and DEX and also a multi-dose of DEX and MP will be administered orally to healthy volunteers (total n=50).

Conditions

  • Healthy Volunteers

Interventions

  • MethylprednisoneDrug

    12 mg of methylprednisone (3 pills of 4 mg each) administered orally in a single dose.

  • MethylprednisoneDrug

    12 mg of methylprednisone (3 pills of 4 mg each) administered orally every 24 hours during 3 days.

  • DeflazacortDrug

    30 mg of deflazacort (1 pill) administered orally in a single dose.

  • DexamethasoneDrug

    4 mg of dexamethasone (1 pill) administered orally in a single dose.

  • DexamethasoneDrug

    2 mg of dexamethasone (1/2 pill) administered orally every 12 hours during 5 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Urine concentration of methylprednisoneTime frame: 0-4h (hours), 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h post-administration
  2. Urine concentration of methylprednisone metabolitesTime frame: 0-4h (hours), 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h post-administration
  3. Urine concentrations of deflazacortTime frame: 0-4h (hours), 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h post-administration
  4. Urine concentrations of deflazacort metabolitesTime frame: 0-4h (hours), 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h post-administration
  5. Urine concentration of dexamethasoneTime frame: 0-4h (hours), 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h, 120-144h post-administration
  6. Urine concentration of dexamethasone metabolitesTime frame: 0-4h (hours), 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h, 120-144h post-administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • IMIM (Hospital del Mar Medical Research Institute)

    Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.